B
Bull
Bull · 25%SCPH
$8.79
Scenario price
$5.670
0.000 (0.00%)At close
Loading chart…
- High
- 5.705
- Open
- 5.680
- VWAP
- 5.67
- Vol
- 10.90M
- Mkt Cap
- 157.56M
- Low
- 5.650
- Amount
- 61.85M
- EV/EBITDA, TTM
- -2.59
scPharmaceuticals Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The Company’s strategy is to develop therapies for subcutaneous administration that have previously been limited to intravenous (IV) delivery. Its commercial product, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infuser. FUROSCIX is a formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self- administered subcutaneously via a single-use, disposable and wearable on-body delivery system. The Company’s pipeline programs include SCP-111 (furosemide injection) 80mg/mL is an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home.
Analyst Ratings (3)
+108.82% upside
Buy
3 Buy
0 Hold
0 Sell
Current: 5.67
Low
5.35
Average
11.84
High
25.00
Maxim
Hold
—
2025-08-26
Maxim
2025-08-26
Price Target
—
Hold
H.C. Wainwright
Buy
$9
2025-08-25
H.C. Wainwright
2025-08-25
Price Target
$9
Buy
Craig-Hallum
Hold
$6
2025-08-25
Craig-Hallum
2025-08-25
Price Target
$6
Hold
HC Wainwright & Co.
Strong Buy
$18
2025-03-20
HC Wainwright & Co.
2025-03-20
Price Target
$18
Strong Buy
Maxim Group
Strong Buy
$12
2025-03-20
Maxim Group
2025-03-20
Price Target
$12
Strong Buy
Valuation Metrics
The current forward P/E ratio for scPharmaceuticals Inc (SCPH) is -2.81, compared to its 5-year average forward P/E of -4.43.
Alphio AI Price Scenarios for SCPH
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding SCPH
Events Timeline
News
7.009-22PRnewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BRY, SCPH, WKHS on Behalf of Shareholders
7.009-16PRnewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SHCO, VRNT, SCPH on Behalf of Shareholders
7.009-16GlobenewswireSHAREHOLDER INQUIRY: Halper Sadeh LLC Probes ZIMV, ARIS, SCPH for Shareholder Interests
8.509-15GlobenewswireShareholder Notice: M&A Class Action Firm Probing the Merger Involving GTLS, SCPH, VTLE, and VRNT
7.008-28PRnewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NWE, BKH, MURA, SCPH on Behalf of Shareholders
SCPH FAQ — answered by Alphio AI
scPharmaceuticals Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The Company’s strategy is to develop therapies for subcutaneous administration that have previously been limited to intravenous (IV) delivery. Its commercial product, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infuser. FUROSCIX is a formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self- administered subcutaneously via a single-use, disposable and wearable on-body delivery system. The Company’s pipeline programs include SCP-111 (furosemide injection) 80mg/mL is an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
3 analysts cover SCPH: 3 rate it Buy, 0 Hold and 0 Sell. The average price target is 11.84.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.